Kyntra Bio
(NASDAQ) KYNB
Kyntra Bio Financials at a Glance
Market Cap
$30.52MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$7.44M
Net Income (TTM)
$163.62M
EPS (TTM)
$27.47
P/E Ratio
0.27
Dividend
$0.00
Beta (Volatility)
1.54 (High)
Dividend
$0.00
Beta (Volatility)
1.54 (High)
Price
$7.62
Volume
155
Open
$7.45
Price
$7.62
Volume
155
Open
$7.45
Previous Close
$7.62
Daily Range
$7.45 - $7.64
52-Week Range
$5.62 - $12.60
Estimated Earnings Date
Aug 10, 2026
Dividend
$0.00
Beta (Volatility)
1.54 (High)
Price
$7.62
Volume
155
Open
$7.45
Previous Close
$7.62
Daily Range
$7.45 - $7.64
52-Week Range
$5.62 - $12.60
Estimated Earnings Date
Aug 10, 2026
KYNB News
Why FibroGen Got Mashed on Monday
![Enrique-Conterno[1]](https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F552569%2Fenrique-conterno1.jpg&w=3840&op=resize)
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Kyntra Bio
Industry
Biotechnology
Sector
Health CareEmployees
34
CEO
Thane Wettig, MBA
Website
www.fibrogen.comHeadquarters
San Francisco, CA 94133, US
KYNB Financials
Key Financial Metrics (TTM)
Gross Margin
45.11%
Operating Margin
-603.83%
Net Income Margin
2199.42%
Return on Equity
-234.28%
Return on Capital
-82.69%
Return on Assets
149.24%
Earnings Yield
3.70%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$30.52MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
4.05M
Volume
155
Avg. Volume
18.40K
Financials (TTM)
Gross Profit
$3.36M
Operating Income
-$44.92M
EBITDA
-$56.06M
Operating Cash Flow
-$21.38M
Capital Expenditure
-$22.00K
Free Cash Flow
-$21.40M
Cash & ST Invst.
$87.24M
Total Debt
$19.25M
Kyntra Bio Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$3.74M
+36.5%
Gross Profit
-$368.00K
-117.0%
Gross Margin
-9.84%
N/A
Market Cap
$30.52MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$897.73K
N/A
Employees
34
N/A
Net Income
-$15.20M
-427.6%
EBITDA
-$12.70M
+10.5%
Quarterly Fundamentals
Total Cash
$87.24M
+159.6%
Total Debt
$19.25M
-73.8%
Accounts Receivable
$5.04M
+3328.6%
Inventory
$3.38M
+7.3%
Long Term Debt
$19.25M
-73.8%
Short Term Debt
$0.00
N/A
Return on Assets
1.49%
N/A
Return on Invested Capital
-55.11%
N/A
Free Cash Flow
-$13.89M
-613.8%
Operating Cash Flow
-$13.89M
-610.7%